SPRY2 and epilepsy: While astrogliosis is enhanced in Spry2/4+/− mice, neuronal cell loss and GCD are clearly reduced indicating that Spry2/4 may serve as pharmacological targets in epilepsy or in other neurodegenerative diseases.